Search Results - Sendur, MA

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study

    Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study by Urun, Yuksel, Yasar, H Arzu, Turna, Hande, Esin, Ece, Sedef, A Murat, Alkan, Ali, Oksuzoglu, Berna, Ozdemir, Nuriye, Sendur, MA Nahit, Sezer, Ahmet, Kılıckap, Saadettin, Utkan, Gungor, Akman, Tulay, Akbulut, Hakan, Celik, Ismail, Abalı, Huseyin

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study

    Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study by Arzu Yaşar, H, Turna, Hande, Esin, Ece, Murat Sedef, A, Alkan, Ali, Oksuzoglu, Berna, Ozdemir, Nuriye, Sendur, MA Nahit, Sezer, Ahmet, Kılıckap, Saadettin, Utkan, Gungor, Akbulut, Hakan, Celik, Ismail, Abalı, Huseyin, Urun, Yuksel

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    EE193 The Health Impact Projection Model of the PD-1/PD-L1 Inhibitor Class in Cancer Care in Turkey

    EE193 The Health Impact Projection Model of the PD-1/PD-L1 Inhibitor Class in Cancer Care in Turkey by Akpamuk, U, Hughes, R, Swales, O, Oyan, B, Kilickap, S, Demirci, U, Sendur, MA, Sonmez, O, Yazici, O, Malhan, S, Oksuz, E, Tuzer, E, Akyol Ersoy, B, Poellinger, B

    Published in Value in health
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?

    Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter? by Ürün, Yüksel, Yaşar, H Arzu, Turna, Hande, Kılıçkap, Saadettin, Sezer, Ahmet, Öksüzoğlu, Berna, Özdemir, Nuriye, Şendur, MA Nahit, Abalı, Hüseyin

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  5. 5
    Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

    Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma by Fléchon, Aude, Morales-Barrera, Rafael, Powles, Thomas, Alva, Ajjai, Özgüroğlu, Mustafa, Csöszi, Tibor, Loriot, Yohann, Rodriguez-Vida, Alejo, Géczi, Lajos, Cheng, Susanna Y, Fradet, Yves, Oudard, Stéphane, Vulsteke, Christof, Gunduz, Seyda, Mamtani, Ronac, Yu, Evan Y, Montesa Pino, Alvaro, Anido, Urbano, Sendur, Mehmet A N, Gravis, Gwenaelle, Révész, János, Kostorov, Vladimir, Huillard, Olivier, Ma, Junshui, Rajasagi, Mohini, Vajdi, Amir, Lunceford, Jared, Cristescu, Razvan, Imai, Kentaro, Homet Moreno, Blanca, Matsubara, Nobuaki

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Statut antioxydant chez des patientes ostéoporotiques : une étude contrôlée

    Statut antioxydant chez des patientes ostéoporotiques : une étude contrôlée by Faruk Sendur, Omer, Turan, Yasemin, Tastaban, Engin, Serter, Mukadder

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: